Anti-VEGF protocol with guided laser reduces treatment burden but adds no visual acuity benefit

David M. brown
NEW ORLEANS — At 2 years, the TREX-DME trial demonstrated that adjuvant focal laser treatment provided no statistically significant anatomic benefit in patients treated with Lucentis, while a treat-and-extend protocol, with laser or without, did reduce treatment burden, David M. Brown, MD, said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.
The objective of the trial was to compare monthly Lucentis (ranibizumab, Genentech) vs. treat-and-extend ranibizumab vs. guided laser plus treat-and-extend ranibizumab in patients with diabetic

Full Story →